Skip to main content
Theraclion SA logo

Theraclion SA — Investor Relations & Filings

Ticker · ALTHE ISIN · FR0010120402 LEI · 9695007X7HA7A1GCYD29 PA Manufacturing
Open in API
Filings indexed 399 across all filing types
Latest filing 2020-06-19 AGM Information
Country FR France
Listing PA ALTHE

About Theraclion SA

https://www.theraclion.com/?_ga=2.14878…

Theraclion SA is a medical device company specializing in the development and marketing of non-invasive therapeutic solutions using High-Intensity Focused Ultrasound (HIFU). The company's technology, known as echotherapy, provides a non-surgical alternative for tissue ablation. Its flagship product, SONOVEIN®, is a robotic solution for the non-invasive treatment of varicose veins. The system uses external ultrasound beams to ablate the target vein without incisions, catheters, or sedation, allowing for immediate patient recovery. Theraclion also developed ECHOPULSE®, a system for the treatment of thyroid nodules and breast fibroadenomas. The company's core focus is on providing precise, non-invasive treatments that reduce risks and recovery time compared to traditional surgical procedures.

Recent filings

Filing Released Lang Actions
Modalités de mise à disposition des documents préparatoires à l'AG
AGM Information Classification · 98% confidence The document is titled "Assemblée générale ordinaire et extraordinaire de Theraclion du 18 juin 2020" (Ordinary and Extraordinary General Meeting of Theraclion of June 18, 2020) and explicitly announces that all resolutions proposed by the board were adopted by shareholders. It details the approval of 2019 annual accounts, renewal of director mandates, and authorizations for share buybacks and capital increases. This content directly relates to the proceedings and outcomes of a General Meeting. Since it reports the results of the shareholder vote, the most appropriate classification is AGM Information (AGM-R), which covers presentations and materials shared during the AGM. While it mentions voting results, the primary focus is the announcement of the meeting's outcome and approvals, fitting AGM-R better than DVA (which is strictly for the official declaration of voting results). Given the context of an AGM announcement, AGM-R is the best fit.
2020-06-19 French
Inside Information / Other news releases
Capital/Financing Update Classification · 99% confidence The document is a press release dated January 30, 2020, providing clarification on the company's cash flow situation, mentioning existing financing agreements (tranches 2 and 3), and providing sales growth expectations for 2020 and beyond, aiming for break-even in 2022. This content focuses on financial status, funding, and outlook, which aligns best with a general financial update or capital/financing activity announcement. Since it is not a full quarterly report (IR) or an annual report (10-K), and it specifically discusses financing agreements and cash requirements, the 'Capital/Financing Update' (CAP) category is the most appropriate fit. It is not a formal earnings release (ER) which usually contains structured P&L/Balance Sheet data, nor is it a management discussion and analysis (MDA) which is typically longer and more detailed.
2020-01-30 English
Informations privilégiées / Autres communiqués
Capital/Financing Update Classification · 99% confidence The document is a press release dated January 30, 2020, titled "Theraclion apporte des précisions sur sa situation de trésorerie" (Theraclion provides details on its cash position). It discusses the company's cash balance (€1.4M as of Dec 31, 2019), details about an unexercised financing agreement (€11.8M over three years), and projections for sales growth and reaching break-even. This content focuses on financial status, funding, and near-term outlook, which aligns best with an Earnings Release (ER) or a general financial update. Since it is a press release providing key financial highlights (cash, financing, sales outlook) rather than a comprehensive quarterly report (IR) or a full management discussion (MDA), 'ER' is the most appropriate classification. The length (under 5,000 characters) suggests it is an announcement rather than a full report, but ER is a specific announcement type.
2020-01-30 French
Informations privilégiées / Information sur chiffre d’affaires annuel
Earnings Release Classification · 100% confidence The document is dated January 27, 2020, and explicitly announces the company's 'chiffre d'affaires pour l'année 2019, clôturant le 31 décembre' (revenue for the year 2019, closing December 31st). It provides detailed financial figures for 2019 versus 2018, including sales of systems, consumables, and services, and includes management commentary on performance and outlook. This structure—a formal announcement of annual financial results, often released before the full 10-K filing—is characteristic of an Earnings Release (ER). While it contains some forward-looking statements and operational updates, its primary function is the release of the annual financial performance summary for the preceding year. FY 2019
2020-01-27 French
Inside Information / Information on annual revenues
Earnings Release Classification · 100% confidence The document is titled with a summary of performance for the year 2019, announced on January 27, 2020. It presents detailed annual sales figures (€ 2,784 thousand in 2019 vs. € 1,928 thousand in 2018), operational highlights (system sales, recurring revenue), cash position as of December 31, 2019, and an outlook for 2020. This structure, covering a full fiscal year's performance and financial results, strongly indicates an Annual Report or a document closely related to it, such as an Earnings Release (ER) or Management Discussion & Analysis (MDA). Since it provides detailed financial tables and a comprehensive review of the entire year's operations, it is more substantial than a typical ER (which is usually just highlights) and lacks the formal structure of a 10-K filing (which is a specific SEC form). Given the context of a European company (Theraclion, listed on Euronext Growth Paris) reporting full-year results, this is best classified as an 'Interim / Quarterly Report' (IR) if it were a half-year report, but since it covers the full year and includes detailed financial breakdowns, it functions as the company's primary annual financial disclosure outside of the formal 10-K structure. However, the definitions provided do not have a specific 'Full Year Financial Report' code distinct from 10-K or IR. Since it is a comprehensive report of the full year's financial results, it aligns most closely with the scope of an Annual Report (10-K) or a detailed Interim Report (IR). Given the comprehensive nature and full-year scope, and lacking the specific SEC 10-K header, it fits the description of a comprehensive financial report for a period shorter than a year (IR) if we interpret 'Interim' loosely to mean 'non-10-K annual report', or it could be considered an MDA if it were purely management commentary. Since it contains hard financial tables and is a year-end summary, it is most analogous to a comprehensive financial report. In the absence of a specific 'Annual Financial Report' code other than 10-K, and noting that it is a detailed financial summary, I will classify it as an Interim Report (IR) as it is a comprehensive financial statement release, even though it covers a full year, as it is not the formal 10-K filing. FY 2019
2020-01-27 English
Acquisition ou cession des actions de l'émetteur / Information relative au contrat de liquidité
Regulatory Filings Classification · 99% confidence The document is titled "BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE CONTRACTE AVEC LE CREDIT INDUSTRIEL ET COMMERCIAL" (Half-yearly balance sheet of the liquidity contract concluded with CREDIT INDUSTRIEL ET COMMERCIAL). It details transactions and holdings related to a liquidity contract over the second half of 2019 (2ème semestre 2019). This type of regular, periodic report concerning market operations, often related to share trading or financing agreements, fits best under the category of financial updates or regulatory disclosures. Since it is a specific, periodic report on a financing/liquidity agreement, and not a full annual report (10-K) or a standard quarterly earnings report (ER), it is most closely related to Capital/Financing Updates (CAP) or potentially a specialized regulatory filing (RNS). Given the focus on the liquidity contract performance over a defined period (half-year), CAP is a strong candidate, but because it is a specific contractual report rather than a general financing announcement, and given the lack of a perfect fit, it leans towards a specialized regulatory disclosure. However, liquidity contracts are fundamentally about capital management and market stability. Comparing the options, 'CAP' (Capital/Financing Update) covers financing activities. If this were a standard regulatory filing not covered elsewhere, RNS would apply. Since it details the status of a liquidity contract, which is a financing mechanism, CAP is the most appropriate specific category. The document is a report itself, not an announcement of a report, so RPA/RNS fallback is less likely unless CAP is deemed too broad. Given the content is a 'Bilan Semestriel' (Half-Yearly Report) on a financing contract, CAP is selected.
2020-01-08 French

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.